KR100853439B1 - Erectile dysfunction treating agent comprising main components of acanthopnax divaricatus var.albeofructus hs-70 extract - Google Patents

Abstract

A therapeutic agent comprising a compound isolated and purified from an alcohol extract of Acanthopanax divaricatus var. albeofructus is provided to show corpus cavernosum relaxation effect and generate NOx in endothelial cells, thereby being usefully used for treating erectile dysfunction. An agent for treating erectile dysfunction comprises sesamin, tortoside A, syringaresinol or elutheroside E, which is isolated from an alcohol extract of Acanthopanax divaricatus var. albeofructus.

Description

Erectile dysfunction treating agent comprising main components of Acanthopnax divaricatus var.albeofructus HS-70 extract}

1 is a diagram showing the process of obtaining 70% ethanol extract (HS-70) of the white hairy oak tree trunk.

Figure 2 is a diagram showing the separation and purification process of CHCl ₃ fraction of the stem of the white hairs.

3 is a white hairy stems of orange stem H ₂ O Figure shows the separation and purification process of fractions.

FIG. 4 is an HPLC chromatogram of white hawthorn stem 70% alcohol extract (HS-70).

5 is a graph showing the effect of the compound of the present invention on nitric oxide production in vascular endothelial cells.

6 is a fluorescence micrograph showing the effect of the compound of the present invention on nitric oxide production in vascular endothelial cells.

The present invention relates to an erectile dysfunction comprising a compound separated and purified from white hairy ogacico alcohol extract, and more particularly comprising a substituted octahydro-2, 6-diphenylpentalene derivative isolated from white hairy ogacico alcohol extract. An erectile dysfunction treatment agent.

Penile erection is a complex physiological reaction caused by the overall action of blood vessels, endocrine system, nervous system, etc. A relatively rigid white membrane as the cavernous smooth muscle is relaxed by various stimuli and the pores are expanded and the blood pressure increases due to the expansion of the small arteries. The subarachnoid veins in the small microcavity are pressed by the swelling of the pores, preventing the leakage of venous blood, which leads to increased penile pressure (Lue TF, Tanagho EA., J Urol , 1987, 137, 829). -36). As the physiological phenomenon of penile erection is revealed and the pharmacological action and mechanism of various drugs on cavernous smooth muscle are studied, efforts are being made to use drugs that have a relaxing effect on smooth muscle for the treatment of erectile dysfunction. Current substances that relax cavernous smooth muscle include adrenergic α receptor blockers, cholinergic drugs, NO (Nitric oxide), peptides, prostaglandins, histamines, calcium channel blockers, potassium channel openers, and nonspecific vasodilators (Linet OI). , Ogrinc FG., N Eng J Med , 1996, 334, 873-7; Tong YC et al ., Pharmacology , 1992, 45, 241-9; Miller MA et al ., Int J Impot Res, 1995, 7, 91 -100; Andersson KE, Wagner G., Physiol Rev , 1995, 75, 191-236; Andersson KE, Stief CG., World J Uro , 1997, l15, 14-20; Andersson KE., Pharmacol Rev , 2001, 53 , 417-50).

There is no accurate study of the frequency of erectile dysfunction, but the increase in average life expectancy, the increase in adult disease and diet, the increase of industrial accidents and traffic accidents due to industrial socialization, and the physical fatigue and mental stress caused by complex modern life Erectile dysfunction patients are on the rise. The treatment of erectile dysfunction includes medical treatment such as drug use, male hormone administration, surgical treatment such as vascular surgery, penile implant insertion, and intravascular penile catheter injection. In medical pharmacotherapy, male hormones, yohimbin, apomorphine, trazodone, etc. are generally used, except for severe organic erectile dysfunction. And low therapeutic effects and no reproducible drug (Andersson KE, Pharmacol Rev , 2001, 53, 417-50; Montorsi F et al ., BJU International , 2003, 91, 446-54; Vitezic D , Pelcic JM, Int J Clin Pharmacol Ther , 2002, 40 (9), 393-403), currently Sildenafil is used as the primary treatment for erectile dysfunction (Heaton JP, Dean J, Sleep DJ, Int J Impot Res , 2002, 14, 61-4).

On the other hand, Ogalpi is used as a medicinal herb in herbal medicine, has a hot taste, bitterness, warm properties, and is known to act on the liver, nerves, and nerves to get rid of customs and nourish the essence. In addition, it was used to show the auropathy (sickness caused by the weakness of the five intestines) and the seven statues (seven symptoms caused by the weakness of a man) and to use the legs poorly. It is known to help the body, to improve energy, to clear the mind, to increase the willpower, to prevent the body from becoming light and old, and to cure the bad blood inside the body cleanly and cleanly. It is known to cure various symptoms such as women's ulcers.

Studies on the white hair organolpi were conducted by eleutheroside content analysis (Kang JS et al., Arch Pharm Res., 4 (5): 407-11, 2001), lupane triterpenoids (lupane) triterpenoids) compounds (Oh OJ et al., Chem Pharm Bull. 48 (6): 879-81, 2000) have been reported and there is no report of physiological activity. It has been published in Republic of Korea Patent 0559493 valid for erection.

Accordingly, the present inventors have found that the substituted octahydro-2 and 6-diphenylpentalene derivatives in the process of separating and purifying the active ingredient from 70% ethanol extract of the white hairy hairfish have the effect of relaxing the penile corpus cavernosum and generating nitric oxide in vascular endothelial cells. The present inventors have completed the present invention by revealing that the present pharmacological effect can be used as a therapeutic agent that can improve erectile dysfunction because this pharmacological effect is an important activity for inducing penile erection.

It is an object of the present invention to provide an agent for treating erectile dysfunction comprising a compound isolated from white hairy stamens.

In order to achieve the above object, the present invention provides a method for purifying the substituted octahydro-2, 6-diphenylpentalene derivative from the white hairy.

The present invention also provides an erectile dysfunction therapeutic agent comprising a substituted octahydro-2, 6-diphenylpentalene derivative.

Hereinafter, the present invention will be described in detail.

The present invention

1) extracting the stem of the white hairy ogapi with ethanol;

2) Chromatographic extract of the extract of step 1 H ₂ O Obtaining a fraction or CHCl ₃ fraction; And

3) H ₂ O in step 2 Or it provides a method for separating and purifying the substituted octahydro-2, 6- diphenylpentalene derivatives from the white hairy gagapi comprising the step of separating the main compound from the CHCl ₃ fraction.

The present inventors fractionated the 70% ethanol extract of the stem of the hawthorn stems with CHCl ₃ and H ₂ O to obtain a CHCl ₃ fraction and H ₂ O fraction. CHCl ₃ fractions were subjected to silica gel column chromatography to obtain three fractions, and three compounds were purified purely from the fractions using HPLC. White Hairy Oak Tree H ₂ O The fractions were subjected to MCI-gel CHP20P column chromatography to obtain 6 fractions, and from these fractions, one compound of the main component was purified purely by silica gel column chromatography. As a result of structural identification for each component, Sesamin (SE), Tortoside A (TA), (+)-Syringaresinol (SY) and Eleutheroside E (EE) substituted octahydro-2, 6-diphenylpentalene derivatives Was identified. Substituted octahydro-2, 6-diphenylpentalene derivatives and the respective formulas are as follows. These compounds are found not only in 70% ethanol extracts of white hair organolpi, but also Sesamin (SE), Tortoside A (TA), (+)-Syringaresinol (SY) in organic solvent extracts such as metanole and chloroform, and Eleutheroside E may be isolated and purified in the (EE), Acanthopanax senticosus (Acanthopanax senticosus), island senticosus (Acanthopanax koreanum), private houses during senticosus (Acanthopanax senticosus forma inermis), Jiri senticosus (Acanthopanax chiisanensis), such as containing a variety senticosus and the compound Other plants can be separated and purified in a similar manner.

<Formula 1>

In the above, R ₁ to R ₆ is a C ₁ to C ₄ alkyl group, or within a C ₁ to C ₄ alkoxy group within.

<Formula 2>

Sesamin (SE)

<Formula 3>

Tortoside A (TA)

<Formula 4>

(+)-Syringaresinol (SY)

<Formula 5>

Eleutheroside E (EE)

The present invention also provides an erectile dysfunction therapeutic agent comprising a substituted octahydro-2, 6-diphenylpentalene derivative.

The present inventors sesamin (SE), Tortoside A (substituted octahydro-2, 6-diphenylpentalene derivatives separated and purified above to identify the main component showing the erectile potentiation effect of the white hair organ extract (HS-70) TA), (+)-Syringaresinol (SY) and Eleutheroside E (EE) were performed in vitro.

First, the penis of the rabbit was excised to separate the cavernous smooth muscle, and then a slice was made and connected to an isotropic contraction recorder to record the state of cavernous smooth muscle movement. Smooth muscle sections from which endothelial cells were removed were used after rubbing the cavernous smooth muscle to remove endothelial cells. Specifically, the treated sponges were treated with phenylephrine (phenylhephrine, PHE) to induce a contraction, and then purified from the 70% ethanol extract of the stems of white hairy sesame seed (SE) and tortoside A (TA). ), Siringresinol (SY) and eluteroside E (EE) were administered to record the state of cavernous smooth muscle.

As a result, EE, TA, SY, and SE showed a relaxation effect on rabbit cavernous smooth muscle in concentration-dependent manner, and SY was the best, and SE, TA, and activity were also good (see Table 1).

The present inventors analyzed the effects of organolpi components on nitrogen compound (NOx) production using vascular endothelial cells. Vascular endothelial cells were treated with the compound isolated from the white hairy organ, and then cultured, and the amount of nitrogen compound (NOx) produced from nitrogen monoxide (NO) was analyzed with a nitrogen monoxide analyzer. As a result, the amount of nitrogen monoxide produced in vascular endothelial cells was higher than some of the compounds isolated from albino organs (SY, 70 (HS-70), SE, TA) compared to the untreated group (DMSO solvent only). That is, compared to VEGF, the endothelial growth factor, it increased the production of nitric oxide in vascular endothelial cells by 3.1 times, 70 times 2.1, SE 1.9 times, and TA 1,5 times. See Table 2).

The present inventors incubated the vascular endothelial cells with or without treatment of each component separated from the white hair organolpi, loaded into a parallel plate flow chamber, excited with filtered light from a mercury lamp, confirmed by confocal microscopy and fluorescence intensity. Measured. As a result, the intracellular concentration of nitric oxide in vascular endothelial cells was higher in the SY, 70, SE TA compound treatment group than the untreated group (DMSO solvent only). In addition, among these compounds, the effect of increasing the concentration of nitric oxide in endothelial cells was the highest in SY (see Figure 2).

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are only for exemplifying the contents of the present invention and do not limit the present invention.

<Example 1> Fraction of 70% ethanol extract (HS-70) of the stem of St. Paulis chinensis

4 liters of 70% ethanol was added to 5 Kg of the white hairy oak tree trunk (Cheonan Material Co., Ltd. Receiving Ogalpi Farm) and heated at 70 degrees for 5 hours, followed by concentration to obtain 265 g of the extract. To this fraction into CHCl ₃ and H ₂ O to give the CHCl ₃ fraction and 110 g H ₂ O fraction 120 g.

Example 2 White Hairy Cucurbita Stem CHCl ₃ Separation and purification of fractions

Silica gel column chromatography (Merck, solvent: CHCl ₃ : MeOH = 10: 1) was used as a developing solvent of CHCl ₃ fraction, CHCl ₃ , to obtain three fractions. Sesamin 34 mg in fraction F-1 (8.8 g), tortoside A 110 mg in fraction F-2 (40 g), and 160 g of syringaresinol in fraction F-3 (45 g) were purified and purified by HPLC. Conditions: HPLC column, YMC Pack Pro C18, 250 x 20 mm, YMC Co. LTD, Japan; Solvent, Water: Acetonitril = 100% concentration gradient starting at 90:10)

Example 3 White Hairy Oyster Stem H ₂ O Separation and purification of fractions

White Hairy Oak Tree H ₂ O 120 g of the fractions were purified by MCI-gel CHP20P column chromatography (Mitsubishi Chem Corp, Japan) using H ₂ O-MeOH gradient solvent system. 80; 20, 60:40, 40:60, 20:80. It eluted on 0: 100 conditions. Thus, six fractions were obtained and purified purely 500 mg of eleutheroside E, the main component of fraction W-3.

Example 3 Structure Identification of Isolated Components

<3-1> Structural Analysis of Sesamin (SE)

Colorless prisms, mp 122-124 ° C., ¹ H-NMR (300 MHz, CDCI ₃ ) δ: 3.07 (2H, m, H-1 and H-5), 3.90 (2H, dd, J = 9.2, 3.5 Hz, He-4 and He-8), 4.25 (2H, dd, J = 8.7, 7.0 Hz, Ha-4 and Ha-8), 4.74 (2H, d, J = 4.3 Hz, H-2 and H-6) , 5.96 (4H, s, 2 x OCH2O), 6.80 (4H, m, H-5 ', H-5 ", H-6' and H-6"), 6.86 (2H, m, H-2 'and H-2 ″). ¹³ C-NMR (75 MHz, CDCI ₃ ) δ: 148.3 (s, C-3 ′ and C-3 ″), 147.5 (s, C-4 ′ and C-4 ″), 135.5 (s, C-1 ′ And C-1 ″), 119.7 (s, C-6 ′ and C-6 ″), 108.5 (s, C-5 ′ and C-5 ″), 106.8 (s, C-2 ′ and C-2 ″), 101.4 (t, O-CH ₂ -O), 86.1 (d, C-2 and C-6), 72.1 (t, C-4 and C-8), 54.7 (d, C-1 and C -5).

<3-2> Structural Analysis of Tortoside A (TA)

slightly yellow powder, ¹ H-NMR (300 MHz, CD ₃ OD): 6.67 (1H, s, H-2, 6), 4.78 (1H, d, J = 4.1 Hz H-7), 3.14 (1H, m , H-8), 4.29 (1H, m, H-9), 3.91 (1H, m, H-9), 3.87 (6H, s, H-3, 5-OMe), 6.73 (1H, s, H -2 ＇, 6＇), 4.73 (1H, d, J = 4.4 Hz, H-7 '), 3.14 (1H, m, H-8'), 4.29 (1H, m, H-9 '), 3.91 (1H, m, H-9 '), 3.85 (6H, s, H-3', 5'-OMe), 4.88 (1H, m, H-1 of Glu), 3.47 (1H, m, H-2 of Glu), 3.21 (1H, m, H-3 of Glu), 3.41 (1H, m, H-4 of Glu), 3.43 (1H, m, H-5 of Glu), 3.69 (1H, dd, J = 11.9, 5.1 Hz, H-6 of Glu), 3.79 (1H, dd, J = 11.9, 2.4 Hz, H-6 of Glu). ¹³ C-NMR (75 MHz, CD ₃ OD): 133.1 (s, C-1), 104.8 (d, C-2, 6), 149.3 (s, C-3, 5), 136.2 (s, C- 4), 87.2 (d, C-7), 55.7 (d, C-8), 72.9 (t, C-9), 56.8 (q, 3, 5-OMe), 139.5 (s, C-1 ') , 104.5 (d, C-2 ', 6'), 154.4 (s, C-3 ', 5'), 135.6 (s, C-4 '), 87.6 (d, C-7'), 55.5 (d , C-8 '), 73.0 (t, C-9'), 57.1 (q, 3 ', 5'-OMe), Glu 105.3 (d, C-1), 75.7 (d, C-2), 78.3 (d, C-3), 71.4 (d, C-4), 77.8 (d, C-5), 62.6 (t, C-6).

<3-3> Structural Analysis of (+)-Syringaresinol (SY)

slightly yellow powder, 313.5-314.4 ° C., ¹ H-NMR (300 MHz CD ₃ OD,): 3.14 (2H, m, H-1,5), 4.34 (2H, dd, J = 6.9, 9 Hz, H- 4α), 3.64 (2H, dd, J = 3.6, 9 Hz, H-4β), 4.80 (2H, d, J = 4 Hz, H-2), 6.67 (4H, s, H-2 '), 3.86 (12H, s, 4 x OCH 3). ¹³ C-NMR (75 MHz CD ₃ OD,): 54.5 (d, C-1), 71.7 (t, C-4), 86.6 (d, C-2), 132.2 (s, C-1 '), 103.7 (d, C-2 ′), 148.4 (s, C-3 ′), 135.4 (s, C-4 ′), 55.9 (q, 3′-OMe).

<3-4> Structural Analysis of Eleutheroside E (EE)

white powder mp 250-252 ° C., ¹ H-NMR (300 MHz, DMSO- d ₆ ): 6.66 (4H, s, aromatic, proton), 3.76 (12H, s, 4OCH ₃ ). ¹³ C-NMR (75 MHz, DMSO- d ₆ ): 54.4 (d, C-1, 5), 72.2 (t, C-4, 8), 85.9 (d, C-2, 6), 134.5 (s , C-1 ', 1 ”), 105.1 (d, C-2', 2”), 153.4 (s, C-3 ', 3 ”), 137.9 (s, C-4', 4”), 153.4 (s, C-5 ', 5 ”), 105.1 (d, C-6', 6”), 57.2 (q, 3 ', 3 ”, 5', 5” -OMe), Glu 103.5 (d, C -1 ', 1 ”), 75.0 (d, C-2', 2”), 77.3 (d, C-3 ', 3 ”), 70.7 (d, C-4', 4”), 78.0 (d , C-5 ', 5 ”), 61.7 (t, C-6', 6”)

<Experimental Example 1> Confirmation of Relaxation Effect on the Cavernous Smooth Muscle of Rabbit Penis

Four main components of HS-70: 1. EE (0.8% or more contained in HS-70), 2. TA (in HS-70) Components containing 0.4% or more), 3. SY (component containing 0.3% in HS-70), 4. SE (component containing 0.07% in HS-70) were performed in vitro.

<1-1> Preparation of Rabbit Penile Cavernous Smooth Muscle Sections

The subjects were 85 male and female New Zealand White rabbits (Samtako BIO KOREA, South Korea), 4-6 months of age, similar in structure and physiological erection to the corpus cavernosum of the human body. Sodium pentobarbital was anesthetized through rabbit bile veins at 30-50 mg / kg, and the penis was excised to provide a low-temperature Tyrode solution supplied with a mixture of 95% oxygen and 5% carbon dioxide. ^{composition: (mEq / L) Na +} 153.6, K + 5.3, Ca 2+ 3.0, Mg 2+ 1.2, Cl - 157.2, H 2 PO 4 - 0.6, SO 4 - 1.2, HCO 3 - 7.1 and glucose 5.0; Cavernous smooth muscle was isolated within. Sections of 2 × 2 × 6 mm were made from isolated cavernous smooth muscles and fixed in a 10 ml tissue bath containing a thyroid solution, and connected to an isometric contraction recorder (Biopac systems, USA) to exercise the cavernous smooth muscles. The condition was recorded. The thyroid solution in the tissue container was maintained at 37 ° C., and the oxygen mixture gas was continuously supplied at pH 7.4.

Endothelial cell removal experiments rubbed cavernous smooth muscle to remove endothelial cells (Kim N et al ., J Clin Invest , 1991, 88, 238-42). The cavernous smooth muscle fragments thus prepared were phenylephrine (5 ×). 10 ^-6 M (hereinafter abbreviated as "PHE") induced contraction and confirmed the presence of endothelial cells with or without relaxation by acetylcholine (Ach). After endothelial cell removal, only those specimens with no acetylcholine relaxation or acetylcholine relaxation within 10% prior to de-endothelial manipulation were selected and used as smooth muscle sections from which endothelial cells were removed. Experiments involving no endothelial cell removal used cavernous smooth muscle sections that had already been formed.

<1-2> Determination of ideal tension for isotonic force contraction

The initial tension was maintained at about 2 g and maintained to reach a stable state, and then the degree of contraction was observed by administration of PHE. After that, the endothelial cell sections were washed with thyroid solution to recover to a stable state, and the tension was increased or decreased to observe the degree of contraction by the same concentration of PHE at a stable state. When the time was set as the ideal tension and the drug reaction experiment was started in this ideal tension stable state.

<Experiment 2> Confirmation of the effect on the tension of the cavernous smooth muscle

When the stable corpus callosum smooth muscle was treated with PHE 5 x 10 ^-6 M concentration to induce contraction, the compounds isolated and purified in the above examples were 0.1 mg / ml, 0.2 mg / ml, 0.5 mg / ml, or It was administered at a concentration of 1 mg / ㎖ to record the state of exercise of cavernous smooth muscle in the same manner as in Experimental Example <1-1>.

As a result, the effects of the components of the organgalpi showed that the components EE, TA, SY, and SE showed relaxation effects on the rabbit cavernous smooth muscle in a concentration-dependent manner from 0.1 mg / ml concentration. At this time, SY was the best, followed by TA, SE, EE, in order.

[ Table 1 ] Relaxation effect of each component in rabbit cavernous smooth muscle (%)

Compound concentration EE TA SY SE 0.1mg / mL 10.4 8.3 7.9 10.5 0.2mg / mL 20.2 14.2 32.3 23.4 0.5 mg / mL 29.5 26.2 58.7 33.3 1mg / mL 37.1 40.9 74.7 40.2

Experimental Example 3 Analysis of Effects on NOx Production of Augalpi Components Using Vascular Endothelial Cells

The endothelial cells (Human Umberical Vein Endothelial Cells, isolated from human umbilical cord at Kangwon National University Vascular Research Center) were attached at 2.5 × 10 ⁴ cells / well per well. The day after attachment, the mixture was replaced with medium (M199) to which 1% serum was added, and then, the compound separated from the hairy white hair was treated, and incubated for about 14 hours to produce nitric oxide (NO). After that, 1 ml of cultured medium was taken, put into a tube, centrifuged at 14,000 rpm for 15 minutes, and the supernatant was transferred to a new tube. 500 μl of the supernatant was added to 500 μl of cold 95% ethanol, mixed well with a mixer, and then reacted with ice for 10 minutes. A reaction in which the tube separated 15 minutes and centrifuged at 4 ℃, 14,000 rpm after contains transfer the supernatant to a new tube nitrite (nitrite, NO ₂ ^-) and ^{nitrate-nitrogen} monoxide in order to analyze both the (nitrate, NO ₃₎ An analyzer (NO analyzer, model 7050, Antek co., USA) was used. In the analyzer's reactor, the vanadium (III) solution reacts with the sample, converts it into nitrogen monoxide (NO) form, moves to the nitrogen monoxide analyzer, reacts with ozone (O ₃ ), and generates NO ₂ ^* and oxygen (O ₂ ). . The generated NO ₂ ^* generates energy as it is converted into NO ₂ (nitric acid), and the generated energy is detected by the detector to indicate a value. The nitrite standard solutions 1.63 nM, 16.3 nM, and 163 nM were determined by the NO analyzer (Antek model 7050, USA). 50 μl each was injected into the injector of the heated reactor, and the value of the detector was written down to obtain a linear equation. 50 μl of each sample was injected to determine the amount of nitrogen monoxide using the value of the detector.

The results are shown in Table 2 below.

TABLE 2

sample OD1 OD2 OD (average) NO value NO (Exp-media) Dilution factor (4X) DMSO 173 177 175 1.9 0.1 0.61 SY 50 199 196 198 2.3 0.5 1.90 SE (50) 180 189 185 2.1 0.3 1.17 TA 50 177 183 180 2.0 0.2 0.89 EE (50) 174 172 173 1.9 0.1 0.50 70 (50) 183 190 187 2.1 0.3 1.29 VEGF 237 222 230 2.7 0.9 3.69 Badge alone 164 163 164 1.8 0.0 0.00

Experimental Example 4 Analysis of Nitric Oxide by Confocal Microscopy

HUVEC cells were seeded in gelatin coated 24 well plates at a concentration of 2.5 × 10 ⁴ and incubated for 8 hours in growth medium (M199 + 20% FBS + 5,000 U / mL Heparin + 3 ng / mL bFGF). After exchange with medium (M199) to which 1% serum was added, each of the components separated and purified above was incubated for 14 hours with or without treatment. HUVECs were labeled with 10 mol / L DAF-FM diacetate (Molecular Probe, USA) at 37 ° C. in serum-free M199 medium (Gibco-BRL, USA) for 30 minutes each and loaded into a parallel plate flow chamber (SEC, Korea) And excited with filtered light from a mercury lamp. Upon excitation with light at a wavelength of 488 nm, DAF emitted fluorescence at the wavelength of 515 nm, which was confirmed by confocal microscopy (Atto Bioscience, USA). Fluorescence intensities were then analyzed with Image-Pro Plus v4.5 software (Media Cybernetics, USA).

As a result, the intracellular concentration of nitric oxide in vascular endothelial cells was higher in the SE, HS-70, SY compound treatment group than the untreated group (treated only DMSO solvent). In addition, among these compounds, the effect of increasing the concentration of nitric oxide in endothelial cells was the highest in SY (see Fig. 2).

As described above, Sesamin, Tortoside A, Syringaresinol or Eluteroside E, purified from the white hairy ogaci stem ethanol extract of the present invention, penis It is excellent in the ability to increase the erectile power of the penis because it has a cavernous relaxation effect and the effect of generating nitrate on the vascular endothelial cells, it can be useful as a erectile dysfunction treatment.

Claims (7)

An agent for treating erectile dysfunction comprising any one selected from the group consisting of sesamin, Tortoside A, siringaresinol or Elutheroside E. delete delete delete delete delete delete

Images